Clinical Trials

Numerous clinical trials evaluate (-)-isoproterenol hydrochloride across diverse conditions, ranging from autonomic nervous system disorders—such as postural tachycardia syndrome, orthostatic hypotension, and dopamine beta-hydroxylase deficiency—to anorexia nervosa, acute intraoperative hypotension, coronary disease, and hematological therapy contexts. Spanning Early Phase 1 through Phase 4, these studies are sponsored by academic and clinical research institutions including Vanderbilt University Medical Center, the Laureate Institute for Brain Research, and the University of Calgary. The overall trial portfolio encompasses completed studies, active recruiting efforts, protocols enrolling by invitation, and unconfirmed status records.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06643221 RECRUITING
Leukemia; Hematopoetic Stem Cell Transplantation; Donor Lymphocyte Infusion; CAR T-Cell Therapy; Lymphoma; Cell Therapy
University of Arizona
 2018-01-24 EARLY_PHASE1
NCT05997732 RECRUITING
Vasoconstriction; Vasodilation
University of Alberta
 2023-10-31 PHASE4
NCT05219799 RECRUITING
Obesity; Vasodilation; Healthy
University of Missouri-Columbia
 2023-03-14 EARLY_PHASE1
NCT06520982 RECRUITING
Women; Sympathetic Nervous System; Aging; Blood Flow
University of Missouri-Columbia
 2024-09-20 EARLY_PHASE1
NCT02725060 ENROLLING_BY_INVITATION
Postural Orthostatic Tachycardia Syndrome; Postural Tachycardia Syndrome; Tachycardia; Arrhythmias, Cardiac; Autonomic Nervous System Diseases; Orthostatic Intolerance; Cardiovascular Diseases; Primary Dysautonomias
Vanderbilt University Medical Center
 2016-02
NCT02615119 COMPLETED
Anorexia Nervosa; Major Depressive Disorder; Generalized Anxiety Disorder; Panic Disorder; Brain Injury
Laureate Institute for Brain Research, Inc.
 2015-10-01
NCT03019081 UNKNOWN
Anorexia Nervosa
Laureate Institute for Brain Research, Inc.
 2017-01
NCT00748059 COMPLETED
Autonomic Nervous System Diseases; Orthostatic Hypotension; Dopamine Beta-Hydroxylase Deficiency; Orthostatic Intolerance
Vanderbilt University Medical Center
 1996-12 PHASE1
NCT02726620 COMPLETED
Hypotension
Vanderbilt University Medical Center
 2017-01-05
NCT02524145 COMPLETED
Heart Failure
University of Texas Southwestern Medical Center
 2015-06
NCT03032965 COMPLETED
Atrial Fibrillation
University of Michigan
 2011-10 PHASE2
NCT02286934 COMPLETED
Healthy
Seoul National University Hospital
 2014-09 PHASE1
NCT01377636 COMPLETED
Intraoperative Awareness
NYU Langone Health
 2009-08
NCT00624416 COMPLETED
Lipoma
Pennington Biomedical Research Center
 2007-10 PHASE1; PHASE2
NCT00323843 UNKNOWN
Kidney Stone; Ureteroscopy
Fredericia Hosptial
 2006-06 PHASE2
NCT00226551 COMPLETED
Coronary Disease
Hadassah Medical Organization
 1999-08
NCT00428428 COMPLETED
Kidney Stone; Unexplained Haematuria; Benignant Tumour Mass in the Upper Urinary Tract
Fredericia Hosptial
 2007-02 PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-05)

Check the (-)-Isoproterenol hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a non-selective agonist of beta-adrenergic receptors, (-)-isoproterenol hydrochloride binds to surface receptors to activate adenylyl cyclase, driving an elevation in intracellular cyclic adenosine monophosphate (cAMP) and subsequent protein kinase A activation. This intracellular signaling cascade induces cardiac sinoatrial node stimulation, enhances myocardial contractility, and promotes vascular and airway smooth muscle relaxation, underpinning its therapeutic utility in clinical trials evaluating autonomic nervous system disorders, hypotension, and cardiovascular responsiveness.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.